SCHEMBL19975313

SCHEMBL19975313

CC(C(=O)C(=O)NCc1cccc(Cl)c1)N(C=O)CC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPT P10636 1/20 0.45
ALOX12 P18054 1/20 0.45
F2 P00734 3/20 0.43
EPHX2 P34913 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
EPHX1 P07099 1/20 0.40
P2RX7 Q99572 1/20 0.40
CTSV O60911 2/20 0.39
CTSL P07711 2/20 0.39
CTSS P25774 2/20 0.39
CTSK P43235 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ERCC1 P07992 1/20 0.39
ERCC4 Q92889 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974794 0.90 ALDH1A1 (0.42) ALDH1A1GAAL3MBTL1RXFP1P2RX7
SCHEMBL19975182 0.85 ALDH1A1 (0.48) ALDH1A1GAAL3MBTL1MAPTALOX12
SCHEMBL19975379 0.84 ALDH1A1 (0.51) ALDH1A1GAAL3MBTL1MAPTALOX12
SCHEMBL19975402 0.81 MASP2 (0.45) RXFP1
SCHEMBL19974709 0.81 OPRM1 (0.46) ALDH1A1GAAL3MBTL1NPC1RAB9A
SCHEMBL19975522 0.80 GABRP (0.41) NPC1RAB9ARXFP1P2RX7
SCHEMBL19975432 0.79 GABRP (0.43) GAANPC1RAB9ARXFP1
SCHEMBL21183521 0.77 MAPK1 (0.42) ALDH1A1GAAL3MBTL1MAPTALOX12
SCHEMBL19975316 0.76 MASP2 (0.44) ALDH1A1L3MBTL1MAPTRXFP1
SCHEMBL19975248 0.75 ALDH1A1 (0.41) ALDH1A1GAAL3MBTL1RXFP1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C ALDH1A1 2271/4885GAA 75/4885L3MBTL1 1238/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C ALDH1A1 2673/4885GAA 107/4885L3MBTL1 1885/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C ALDH1A1 2271/4885GAA 75/4885L3MBTL1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.